Study of Patient Use and Perception of the Travatan Dosing Aid

NCT ID: NCT00626067

Last Updated: 2016-11-10

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE4

Total Enrollment

45 participants

Study Classification

INTERVENTIONAL

Study Start Date

2006-09-30

Study Completion Date

2007-02-28

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The primary objective of this study is to determine the opinions of patients who are given the Travatan Compliance Monitoring Dispenser to use to dispense their Travatan glaucoma drops.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Patients enrolled in this study will use the new Travatan compliance monitoring dispenser for 6 weeks. Patients will be informed that some, but not all, patients' compliance will be monitored by the device. Patients are randomly assigned to one of three groups (proportionally in a 2/2/1 ratio):

1. Fully functional Travatan compliance monitor
2. Travatan compliance monitor with LCD display and alarms disabled, but compliance monitoring intact
3. Travatan compliance monitor with LCD display, alarms and compliance monitor disabled.

At end of study, patients fill out questionnaire assessing

1. Patient opinion regarding device: ease of use of new device; preference vs Travatan use without device, etc
2. patient's belief as to whether their compliance was monitored or not

Rates of adherence are compared across groups and with regard to patients' reported beliefs as to whether they were monitored.

The design of this study should allow the clinicians to ethically monitor compliance in patients who do and do not believe that they are being monitored. The use of monitoring devices without a functioning display and alarm should lead to some patients believing that they are not being monitored. As patients are told at the outset that they may or may not be monitored, this should be an ethically acceptable design. However, the collected data will allow a preliminary assessment of the impact of the patients' beliefs as to whether they are being monitored on their actual compliance, and hence an additional potential value of the device.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Glaucoma

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

Travatan Dosing Aid compliance monitoring dispenser

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

SINGLE_GROUP

Primary Study Purpose

SUPPORTIVE_CARE

Blinding Strategy

DOUBLE

Participants Investigators

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

1 Fully functional monitoring device

Fully functional monitoring device

Group Type ACTIVE_COMPARATOR

Fully functional monitoring device

Intervention Type DEVICE

Pt received fully functional monitoring dispenser for use with their Travatan eye drops

2 Partially functional monitoring device

Partially functional monitoring device

Group Type ACTIVE_COMPARATOR

Partially functional monitoring device

Intervention Type DEVICE

Patient received a particually functional Travatan Compliance Monitoring Dispenser

3 Non-functional monitoring device

Non-functional monitoring device

Group Type SHAM_COMPARATOR

Non-functional monitoring device

Intervention Type DEVICE

Patient received a non functioning Travatan Compliance Monitoring Dispenser

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Fully functional monitoring device

Pt received fully functional monitoring dispenser for use with their Travatan eye drops

Intervention Type DEVICE

Partially functional monitoring device

Patient received a particually functional Travatan Compliance Monitoring Dispenser

Intervention Type DEVICE

Non-functional monitoring device

Patient received a non functioning Travatan Compliance Monitoring Dispenser

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Open angle glaucoma or ocular hypertension
* Presently using Travatan eye drops

Exclusion Criteria

* Allergy to prostaglandin
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Alcon Research

INDUSTRY

Sponsor Role collaborator

Wills Eye

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Jonathon Myers

Attending Surgeon

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Jonathan S. Myers, MD

Role: PRINCIPAL_INVESTIGATOR

Wills Eye Institute

Related Links

Access external resources that provide additional context or updates about the study.

https://doi.org/10.2147/PPA.S114746

Patient Preference and Adherence

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

CMS-06-09

Identifier Type: OTHER

Identifier Source: secondary_id

IRB #06-762E

Identifier Type: -

Identifier Source: org_study_id